NCT05033912View on ClinicalTrials.gov

A Study of CST-2032 in Subjects With Cognitive Impairment

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

May 31, 2022

Conditions
Mild Cognitive Impairment (MCI)Parkinson Disease (PD)
Interventions
DRUG

CST-2032, matching placebo for CST-2032, CST-107

CST-2032 and matching placebo oral liquid; CST-107 white capsules

Sponsors
All Listed Sponsors
lead

CuraSen Therapeutics, Inc.

INDUSTRY

NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment | Biotech Hunter | Biotech Hunter